91 related articles for article (PubMed ID: 16169354)
1. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention.
Chen WH; Lee PY; Ng W; Kwok JY; Cheng X; Lee SW; Tse HF; Lau CP
Am J Cardiol; 2005 Sep; 96(6):760-3. PubMed ID: 16169354
[TBL] [Abstract][Full Text] [Related]
2. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.
Lev EI; Patel RT; Maresh KJ; Guthikonda S; Granada J; DeLao T; Bray PF; Kleiman NS
J Am Coll Cardiol; 2006 Jan; 47(1):27-33. PubMed ID: 16386660
[TBL] [Abstract][Full Text] [Related]
3. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
4. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Chen WH; Lee PY; Ng W; Tse HF; Lau CP
J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
[TBL] [Abstract][Full Text] [Related]
5. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
[TBL] [Abstract][Full Text] [Related]
6. Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.
Muller O; Hamilos M; Bartunek J; Ulrichts H; Mangiacapra F; Holz JB; Ntalianis A; Trana C; Dierickx K; Vercruysse K; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2010 Feb; 105(3):333-8. PubMed ID: 20102944
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
8. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
[TBL] [Abstract][Full Text] [Related]
9. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
10. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
[TBL] [Abstract][Full Text] [Related]
11. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
[TBL] [Abstract][Full Text] [Related]
13. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
14. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
16. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
[TBL] [Abstract][Full Text] [Related]
17. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
[TBL] [Abstract][Full Text] [Related]
18. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
[TBL] [Abstract][Full Text] [Related]
19. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
20. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
